Clinical Trial Update: Study in Healthy Adults Challenged With Enterotoxigenic E. Coli, of the Safety, Tolerability and Anti-Diarrheal Activity of VENBETA6890, an Orally Administered, Human Monoclonal IgA [Phase 1]

View source ↗

Summary

A Phase 1 trial in healthy adults evaluated the safety, tolerability and anti-diarrheal activity of VENBETA6890, an orally administered human monoclonal IgA, in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infectious Diarrhea

Drugs mentioned

• VENBETA6890

Snippet

Sponsor: Mark Klempner | Conditions: Diarrhea Infectious | Phase 1 | Status: COMPLETED